{"pageContent": "Aims: Delaying progression, ameliorating symptoms and maintaining quality of life (QoL) are primary aims of treatment for metastatic castrate-resistant prostate cancer (mCRPC). Real-world rather than clinical trial data about symptoms and side-effects are sparse. In EXTREQOL, patients' QoL, pain and information needs were recorded during treatment.", "metaData": {"source": "Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment\nhttps://pubmed.ncbi.nlm.nih.gov/21208369/"}}